Infection with SARS-CoV-2 variant Gamma (P.1) in Chile increased ICU admission risk three to five-fold

PLoS One. 2023 Mar 24;18(3):e0283085. doi: 10.1371/journal.pone.0283085. eCollection 2023.

Abstract

The 2021 wave of SARS-CoV-2 infection in Chile was characterized by an explosive increase in ICU admissions, which disproportionately affected individuals younger than 60 years. This second wave was also accompanied by an explosive increase in Gamma (P.1) variant detections and the massive vaccine rollout. We unveil the role the Gamma variant played in stressing the use of critical care, by developing and calibrating a queueing model that uses data on new onset cases and actual ICU occupancy, symptom's onset to ICU admission interval, ICU length-of-stay, genomic surveillance, and vaccine effectiveness. Our model shows that infection with the Gamma (P.1) variant led to a 3.5-4.7-fold increase in ICU admission for people younger than 60 years. This situation occurred on top of the already reported higher infection rate of the Gamma variant. Importantly, our results also strongly suggest that the vaccines used in Chile (inactivated mostly, but also an mRNA), were able to curb Gamma variant ICU admission over infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / epidemiology
  • Chile / epidemiology
  • Explosive Agents*
  • Humans
  • Intensive Care Units
  • SARS-CoV-2 / genetics

Substances

  • Explosive Agents

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

Agencia Nacional de Investigación y Desarrollo ANID PIA AFB220003 Dr. Leonardo J. Basso Pontificia Universidad Católica de Chile DIDEMUC COVID 19 Sc-11 Dr. Marcela Ferres Funding: Agencia Nacional de Investigación y Desarrollo grant ANID PIA AFB 220003 (DS, IN, MG, LB), DIDEMUC COVID 19 Sc-11(MF, JAT).